Development of a new automated IL-6 immunoassay

Israeli, Eitan; Okura, Hideaki; Kreutz, Barry; Piktel, Ryan; Hadji, Abbas; Bailin, Tu; Zhang, Lin; Hawksworth, David; Tieman, Bryan C.; Strobel, Carolyn J.; Ziemann, Robert; Leary, Thomas P.; Muerhoff, A. Scott; Hemken, Philip M.

doi:10.1016/j.jim.2022.113262

Cited by 5 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irritant Contact Dermatitis (ICD) is an inflammatory response of the skin to chemical or physical irritants and is characterized by epidermal hyperplasia, inflammatory cell in flux into lesional skin, and inflammatory cytokine release including IL-6, While it is known that IL-6 confers a protective effect to the skin during ICD (Lee et al, 2013).…”

Section: Itmentioning

confidence: 99%

“…In addition, sequential measurements of IL-6 in serum or plasma of patients admitted to the ICU (intensive care unit) showed to be use full in evaluating the severity of (Systemic Inflammatory Response Syndrome) SIRS (Israeli et al, 2022).…”

Section: Itmentioning

confidence: 99%

“…IL-6 is a pleiotropic cytokine with pro-inflammatory, antiinflammatory, and immune modulating functions on numerous cell and tissue types (Tanaka et al,2014;Schaper and Rose-John, 2015). It is produced by numerous immune cells including T cells, neutrophils, macrophages, and nonimmune cells like keratinocytes and fibroblast in the skin , IL-6 has also been shown to affect the function of cells in the skin (Lee, et al, 2013;Oleiwi,2020).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of Interleukin6 (IL-6) levels in Atopic Dermatitis Patients in Thi-Qar province

Naji¹,

Mousa²

2022

UTJsci

View full text Add to dashboard Cite

IL-6 is a pro-inflammatory marker seen in the circulation of atopic disease. The study comprised 90 people of both genders, 45 of whom were patients, and the same number served as controls. Blood samples were obtained from both groups, and the serum levels of IL-6 were estimated using an IL-6 ECLIA kit by Electro-chemilumenescence Immunoassay. The findings of the present study referred that there were elevated sera levels of IL-6 (12.26pg/ml ) in AD patients in contrast to the control groups (4.05pg/ml) with a significant difference . Also, The results revealed an increase in the levels of IL-6 in severe AD patients compared with control group with highly statistically significant(P? 0.01). According to the results of the current study, it can be concluded that IL6 plays a critical role in the pathogenesis of dermatitis, and its elevated levels correlate with the clinical severity of the disease pathogenesis of AD

show abstract

Section: Itmentioning

confidence: 99%

Section: Itmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Interleukin6 (IL-6) levels in Atopic Dermatitis Patients in Thi-Qar province

Naji¹,

Mousa²

2022

UTJsci

View full text Add to dashboard Cite

show abstract

“…For example, the US Food and Drug Administration has issued emergency use authorizations for the Roche Elecsys IL-6 immunoassay and the Siemens ADVIA Centaur IL-6 assay. 6 These assays are diagnostic grade to identify a severe inflammatory response in patients with COVID-19. Once these and immunoassays of other inflammatory biomarkers are officially approved by the US Food and Drug Administration for broader indications, they may have strong potential to facilitate clinical translation of inflammatory biomarkers and cancer outcomes.…”

mentioning

confidence: 99%

“…However, the importance of considering IL-6 and sTNF-αR2 has been increasingly recognized in clinical practice. For example, the US Food and Drug Administration has issued emergency use authorizations for the Roche Elecsys IL-6 immunoassay and the Siemens ADVIA Centaur IL-6 assay . These assays are diagnostic grade to identify a severe inflammatory response in patients with COVID-19.…”

mentioning

confidence: 99%

Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer—Reply

Cheng

Meyerhardt

2023

JAMA Oncol

View full text Add to dashboard Cite

Validation of the novel GLAS algorithm as an aid in the detection of liver fibrosis and cirrhosis based on GP73, LG2m, age, and sex

Hemken,

Qin,

Sokoll

et al. 2023

Clin Proteom

Self Cite

View full text Add to dashboard Cite

Background Diagnosis of liver disease at earlier stages can improve outcomes and reduce the risk of progression to malignancy. Liver biopsy is the gold standard for diagnosis of liver disease, but is invasive and sample acquisition errors are common. Serum biomarkers for liver function and fibrosis, combined with patient factors, may allow for noninvasive detection of liver disease. In this pilot study, we tested and validated the performance of an algorithm that combines GP73 and LG2m serum biomarkers with age and sex (GLAS) to differentiate between patients with liver disease and healthy individuals in two independent cohorts. Methods To develop the algorithm, prototype immunoassays were used to measure GP73 and LG2m in residual serum samples collected between 2003 and 2016 from patients with staged fibrosis and cirrhosis of viral or non-viral etiology (n = 260) and healthy subjects (n = 133). The performance of five predictive models using combinations of age, sex, GP73, and/or LG2m from the development cohort were tested. Residual samples from a separate cohort with liver disease (fibrosis, cirrhosis, or chronic liver disease; n = 395) and healthy subjects (n = 106) were used to validate the best performing model. Results GP73 and LG2m concentrations were higher in patients with liver disease than healthy controls and higher in those with cirrhosis than fibrosis in both the development and validation cohorts. The best performing model included both GP73 and LG2m plus age and sex (GLAS algorithm), which had an AUC of 0.92 (95% CI: 0.90–0.95), a sensitivity of 88.8%, and a specificity of 75.9%. In the validation cohort, the GLAS algorithm had an estimated an AUC of 0.93 (95% CI: 0.90–0.95), a sensitivity of 91.1%, and a specificity of 80.2%. In both cohorts, the GLAS algorithm had high predictive probability for distinguishing between patients with liver disease versus healthy controls. Conclusions GP73 and LG2m serum biomarkers, when combined with age and sex (GLAS algorithm), showed high sensitivity and specificity for detection of liver disease in two independent cohorts. The GLAS algorithm will need to be validated and refined in larger cohorts and tested in longitudinal studies for differentiating between stable versus advancing liver disease over time.

show abstract

Development of a new automated IL-6 immunoassay

Cited by 5 publications

References 14 publications

Evaluation of Interleukin6 (IL-6) levels in Atopic Dermatitis Patients in Thi-Qar province

Evaluation of Interleukin6 (IL-6) levels in Atopic Dermatitis Patients in Thi-Qar province

Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer—Reply

Validation of the novel GLAS algorithm as an aid in the detection of liver fibrosis and cirrhosis based on GP73, LG2m, age, and sex

Contact Info

Product

Resources

About